Gaurav D. Shah
Net Worth

Last updated:

What is Gaurav D. Shah net worth?

The estimated net worth of Dr. Gaurav D. Shah is at least $11,167,130 as of 21 Nov 2024. He owns shares worth $2,100,764 as insider, has earned $2,826,366 from insider trading and has received compensation worth at least $6,240,000 in Rocket Pharmaceuticals, Inc..

What is the salary of Gaurav D. Shah?

Dr. Gaurav D. Shah salary is $1,040,000 per year as Chief Executive Officer & Director in Rocket Pharmaceuticals, Inc..

How old is Gaurav D. Shah?

Dr. Gaurav D. Shah is 50 years old, born in 1975.

What stocks does Gaurav D. Shah currently own?

As insider, Dr. Gaurav D. Shah owns shares in one company:

Company Title Shares Price per share Total value
Rocket Pharmaceuticals, Inc. (RCKT) Chief Executive Officer & Director 707,328 $2.97 $2,100,764

What does Rocket Pharmaceuticals, Inc. do?

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.

Gaurav D. Shah insider trading

Rocket Pharmaceuticals, Inc.

Dr. Gaurav D. Shah has made 10 insider trades between 2019-2024, according to the Form 4 filled with the SEC. Most recently he sold 11,091 units of RCKT stock worth $144,782 on 21 Nov 2024.

The largest trade he's ever made was exercising 290,000 units of RCKT stock on 25 Feb 2020. As of 21 Nov 2024 he still owns at least 707,328 units of RCKT stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 11,091 $13.05 $144,782
Sale
Common Stock 9,650 $18.5 $178,564
Sale
Common Stock 9,790 $23.35 $228,597
Option
Common Stock 7,979 N/A N/A
Option
Restricted Stock Units 7,979 N/A N/A
Option
Restricted Stock Units 9,683 N/A N/A
Option
Common Stock 9,683 N/A N/A
Sale
Common Stock 20,272 $29.84 $604,876
Option
Restricted Stock Units 38,849 N/A N/A
Option
Restricted Stock Units 7,979 N/A N/A
Option
Common Stock 46,828 N/A N/A
Option
Common Stock 7,979 N/A N/A
Option
Restricted Stock Units 7,979 N/A N/A
Sale
Common Stock 4,767 $15.47 $73,750
Option
Common Stock 7,979 N/A N/A
Option
Restricted Stock Units 7,979 N/A N/A
Sale
Common Stock 4,122 $21.38 $88,108
Option
Common Stock 7,979 N/A N/A
Option
Restricted Stock Units 7,979 N/A N/A
Sale
Common Stock 12,194 $19.06 $232,418
Option
Restricted Stock Units 31,440 N/A N/A
Option
Common Stock 31,440 N/A N/A
Purchase
Common Stock 22,000 $17.34 $381,524
Option
Stock Option (Right to Buy) 75,880 $1.69 $128,237
Option
Common Stock 75,880 $1.69 $128,237
Option
Stock Option (Right to Buy) 90,925 $0.44 $40,007
Option
Common Stock 90,925 $0.44 $40,007
Option
Common Stock 290,000 $0.44 $127,600
Option
Stock Option (Right to Buy) 290,000 $0.44 $127,600
Sale
Common Stock 25,000 $16.9 $422,500
Sale
Common Stock 24,900 $17.28 $430,272
Sale
Common Stock 25,000 $16.9 $422,500

Rocket Pharmaceuticals key executives

Rocket Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:

  • Dr. Gaurav D. Shah (50) Chief Executive Officer & Director
  • Mr. John C. Militello CPA, CPA (52) Vice President, Senior Controller & Principal Accounting Officer
  • Mr. Jonathan Schwartz (61) Chief Medical Officer & Senior Vice President of Clinical Devel.
  • Ms. Kinnari Patel M.B.A., Pharm.D., PharmD, MBA (46) Pres, Chief Operating Officer & Head of Devel.